Cyclerion Therapeutics, Inc.

Two companies with different approaches to RNA medicines announced venture capital mega-rounds of $100m or more on 9 August – ADARx Pharmaceuticals, Inc. with a $200m series C financing and Alltrna

Royalty financings were relatively few and far between in the first quarter of 2022, but the number of these financings more than doubled in Q1 of 2023 – from three to seven – and the amount of money

Bogged down by an ongoing spat with its largest shareholder and a share price that continues to flirt with penny stock territory, Mereo BioPharma Group plc announced an updated operating plan on 18

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. AbbVie Continues Development Of Novel S